Paradigm Biocapital Advisors LP: SPYRE THERAPEUTICS INC (SYRE): Quarterly 13F Position History
As of Q2 2026, Paradigm Biocapital Advisors LP reported 3,840,778 shares of SPYRE THERAPEUTICS INC (SYRE), worth $341.0M and representing 6.4% of its 13F equity book. Quarter-over-quarter share count change: + 1,883,512 (+96.2%) . The position first appeared in Q3 2024 and has been disclosed across 8 13F-HR filings in Pactolio's tracked window.
- 3,840,778Shares Held (Latest Filing)
- $341.0MReported Market Value (Latest Filing)
- 6.4%Portfolio Weight (% of 13F Equity Book)
- +1,883,512Quarter-over-Quarter Share Change
- +$242.3MQuarter-over-Quarter Value Change
- 3,840,778Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 8 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q2 2026 | 3,840,778 | +1,883,512 | +96.2% | $341.0M | 6.4% | $88.8 |
| Q1 2026 | 1,957,266 | +490,000 | +33.4% | $98.7M | 2.0% | $50.4 |
| Q4 2025 | 1,467,266 | 0 | – | $48.1M | 1.3% | $32.8 |
| Q3 2025 | 1,467,266 | 403,179 | -21.6% | $24.6M | 0.7% | $16.8 |
| Q2 2025 | 1,870,445 | 256,760 | -12.1% | $28.0M | 1.2% | $15.0 |
| Q1 2025 | 2,127,205 | +600,000 | +39.3% | $34.3M | 1.6% | $16.1 |
| Q4 2024 | 1,527,205 | +259,624 | +20.5% | $35.6M | 1.2% | $23.3 |
| Q3 2024 | 1,267,581 | – | – | $37.3M | 1.3% | $29.4 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares, a quarter-end mark rather than the manager's cost basis. See the full methodology document for the normalization rules.
When did Paradigm Biocapital Advisors LP first disclose a SYRE position in 13F-HR filings?
Paradigm Biocapital Advisors LP first reported SPYRE THERAPEUTICS INC (SYRE) on its 13F-HR filing for the period ending 2024-09-30 (Q3 2024). The position has appeared on 8 reported quarters within Pactolio's tracked window.
What was Paradigm Biocapital Advisors LP's most recent quarter-over-quarter share-count change in SYRE?
Between Q1 2026 and Q2 2026, Paradigm Biocapital Advisors LP added 1,883,512 shares of SYRE (+96.2%), bringing the total reported position to 3,840,778 shares at a market value of $341.0M.
Does the implied price-per-share represent Paradigm Biocapital Advisors LP's cost basis in SYRE?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.